ArthroCare Beats on Both Top and Bottom Lines
ArthroCare (NAS: ARTC) reported earnings on Oct. 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), ArthroCare beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Margins expanded across the board.
ArthroCare recorded revenue of $86.9 million. The nine analysts polled by S&P Capital IQ looked for a top line of $84.6 million on the same basis. GAAP reported sales were 4.4% higher than the prior-year quarter's $83.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.38. The nine earnings estimates compiled by S&P Capital IQ predicted $0.28 per share. GAAP EPS of $0.27 for Q3 were much higher than the prior-year quarter's $0.02 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.9%, 60 basis points better than the prior-year quarter. Operating margin was 15.7%, 710 basis points better than the prior-year quarter. Net margin was 11.5%, 860 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $93.7 million. On the bottom line, the average EPS estimate is $0.36.
Next year's average estimate for revenue is $363.0 million. The average EPS estimate is $1.37.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 133 members out of 269 rating the stock outperform, and 136 members rating it underperform. Among 100 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give ArthroCare a green thumbs-up, and 61 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ArthroCare is outperform, with an average price target of $34.29.
- Add ArthroCare to My Watchlist.
The article ArthroCare Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.